5.88
+9.70%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Mendus AB (publ)
Its shares trade on Nasdaq Stockholm under the ticker IMMU.ST. It has been listed since 22 April 2013. In the fiscal year to 31 December 2022, it reported revenue of SEK 1.8m and a net loss of SEK 138.8m. At that date it held total assets of SEK 620.4m and shareholders' equity of SEK 514.4m.
Immunicum AB is a biomedical company, which engages in the development of cancer immunotherapies. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2013-04-22. The firm develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The firm uses therapeutic vaccines to treat an already existing disease and is thus given to the already sick patients; therapeutic cancer vaccines administered to patients in order to delay or stop tumor cell growth, shrink tumors, prevent relapse, or to kill cancer cells that could not be eliminated with other treatments. The firm has several technology platforms, such as The Combig, Intuvax@, Subcuvax@ and The CD70, among others. The firm has several projects which are related to kidney cancer and liver cancer, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 22 Apr 2013
- Employees
- 11
- Website
- immunicum.se ↗
Leadership
Pay as last reported
- Mr. Sven AndreassonIndependent Chairman of the BoardSEK 705,000
- Dr. Erik MantingChief Executive Officer
- Ms. Lotta FermChief Financial Officer
- Dr. Leopold BerteaChief Technology Officer
- Dr. Alex Karlsson-ParraChief Scientific Officer, since 2020SEK 176,000
- Dr. Jeroen RoversChief Medical Officer
- Mr. Jose OchoaDirector
- Mr. Dharminder ChahalIndependent DirectorSEK 370,000
- Dr. Hans PreustingIndependent DirectorSEK 380,000
- Ms. Helen TuvessonIndependent DirectorSEK 355,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 49
- Environment
- 58
- Social
- 16
- Governance
- 73
- Women in the workforce
- 64.28%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Mendus AB employs 11 full-time staff members in the Health Care sector.
- The company develops cancer immunotherapies using therapeutic vaccines for existing diseases.
- Technology platforms include The Combig, Intuvax@, Subcuvax@, and The CD70 for treatment.
Weaknesses
- The firm has only 11 employees, limiting its operational capacity significantly.
- Therapeutic vaccines are administered to already sick patients with existing conditions.
- The company focuses on kidney cancer and liver cancer projects specifically.
Opportunities
- The firm can use therapeutic vaccines to shrink tumors effectively.
- Immunotherapies may delay or stop tumor cell growth in patients.
- Cancer vaccines can kill cancer cells eliminated by other treatments.
Threats
- The company went IPO on 22 April 2013, facing market pressures.
- Stockholm headquarters location may limit access to diverse global talent.
- Biotechnology sector competition requires continuous innovation in therapeutic vaccine platforms.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.